11,504 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by WCM Investment Management LLC

WCM Investment Management LLC acquired a new position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,504 shares of the medical research company's stock, valued at approximately $871,000.

Other large investors have also recently bought and sold shares of the company. KB Financial Partners LLC purchased a new position in shares of Exact Sciences in the 2nd quarter worth about $32,000. Wolff Wiese Magana LLC increased its holdings in Exact Sciences by 459.5% during the 4th quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company's stock worth $31,000 after purchasing an additional 340 shares during the last quarter. BluePath Capital Management LLC acquired a new position in shares of Exact Sciences in the 3rd quarter worth approximately $33,000. Coppell Advisory Solutions LLC acquired a new position in shares of Exact Sciences in the 2nd quarter worth approximately $46,000. Finally, ST Germain D J Co. Inc. acquired a new position in shares of Exact Sciences in the 2nd quarter worth approximately $46,000. Hedge funds and other institutional investors own 88.82% of the company's stock.

Insiders Place Their Bets

In other Exact Sciences news, Director D Scott Coward sold 1,376 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $61.43, for a total transaction of $84,527.68. Following the completion of the sale, the director now directly owns 41,580 shares in the company, valued at approximately $2,554,259.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director D Scott Coward sold 1,376 shares of the firm's stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $84,527.68. Following the completion of the sale, the director now directly owns 41,580 shares in the company, valued at approximately $2,554,259.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jacob A. Orville sold 966 shares of the firm's stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $61.43, for a total transaction of $59,341.38. Following the completion of the transaction, the insider now directly owns 7,488 shares in the company, valued at approximately $459,987.84. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,113 shares of company stock worth $4,165,273. Company insiders own 1.30% of the company's stock.

Exact Sciences Price Performance

Shares of EXAS traded down $5.99 during trading hours on Monday, reaching $65.35. The stock had a trading volume of 3,060,323 shares, compared to its average volume of 2,308,641. Exact Sciences Co. has a 12 month low of $56.05 and a 12 month high of $100.77. The stock has a market capitalization of $11.86 billion, a PE ratio of -57.32 and a beta of 1.25. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.07 and a current ratio of 2.32. The company's 50-day moving average is $63.33 and its two-hundred day moving average is $65.16.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.26. The business had revenue of $646.89 million during the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative return on equity of 6.60% and a negative net margin of 8.17%. Exact Sciences's quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.72) earnings per share. Research analysts expect that Exact Sciences Co. will post -0.86 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on EXAS. Citigroup restated a "buy" rating and set a $100.00 price objective on shares of Exact Sciences in a research report on Wednesday, April 3rd. Benchmark upgraded Exact Sciences from a "hold" rating to a "buy" rating and set a $91.00 price target on the stock in a report on Tuesday, January 2nd. William Blair reiterated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 22nd. Canaccord Genuity Group lowered their target price on Exact Sciences from $100.00 to $90.00 and set a "buy" rating on the stock in a research note on Thursday, February 22nd. Finally, TheStreet downgraded Exact Sciences from a "c-" rating to a "d+" rating in a research note on Monday, February 26th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $97.44.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.